Impact of ALTTO Results on Patients With HER2-Positive Breast Cancer
In this video, Dr. Sledge discusses what the negative results of the ALTTO trial mean for women with HER2-positive breast cancer.
George W. Sledge, Jr, MD, division of oncology at the Stanford University Medical Center, discusses the results of the ALTTO trial (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation). Following surgery, the trial randomized patients with HER2-positive breast cancer into four treatment arms: trastuzumab alone, lapatinib alone, trastuzumab followed by lapatinib (sequential therapy), or the combination of the two drugs (concurrent therapy).
In this video, Dr. Sledge shares with our audience how despite the negative result, data from this trial may be used to inform other clinical trials, and discusses what other ongoing trials oncologists will be looking at to address questions about adjuvant therapy for women with HER2-positive breast cancer.
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
![A retrospective study shows that [177Lu]Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Ff5ef402e3456a83ca4765506f26761d323734d14-446x339.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "A retrospective study shows that [177Lu]Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.")
